Author

Yutian Zou

Dana-Farber Cancer InstituteORCID 0000-0002-5205-9923Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Jean J. ZhaoiD· 2 shared Anwaruddin MohammadiD· 1 shared Cherubin ManokaraniD· 1 shared David LiuiD· 1 shared Hao GuiD· 1 shared Jerryd Marcus Meade· 1 shared Jiajia CheniD· 1 shared Jing NiiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jean J. ZhaoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

IRG1/itaconate/NRF2/GSH axis in tumor-associated macrophages drives therapy resistance and immune evasion in BRCA1-deficient breast cancer

Yabing Nan, Sophie O'Keefe, Xiadi He, Qingyu Luo, Xiaowei Wu, Jing Ni, Yutian Zou, Jerryd Marcus Meade, Yutong Li, Renlei Ji, Anwaruddin Mohammad, Pankaj Kumar, Qiwei Wang, Jean J. Zhao

This study identifies the IRG1/itaconate/NRF2/GSH axis in TAMs as a driver of PARPi resistance and immune evasion in BRCA1-deficient breast cancer, with pharmacological inhibition showing therapeutic potential.

bioRxiv · Oct 14, 2025 · PreprintCancer Biology

Loss of the tumor suppressor PTEN activates cell-intrinsic interferon signaling to drive immune resistance

Yubao Wang, Cherubin Manokaran, Yutian Zou, Jiajia Chen, Hao Gu, David Liu, Philippe Bousso, Jean J. Zhao, Thomas M. Roberts

This study shows that PTEN loss in cancer cells activates intrinsic interferon signaling, leading to immune resistance and vulnerability to CDK12 inhibition.

bioRxiv · Sep 17, 2025Cancer Biology